A genome-wide association study identifying single nucleotide polymorphisms in the PPFIBP2 gene was predictive for interstitial lung disease in rheumatoid arthritis patients

1. Raghu G. Idiopathic pulmonary fibrosis: new evidence and an im- proved standard of care in 2012. Lancet 2012;380:699–701.

2. Ryu JH, Colby TV, Hartman TE, Vassallo R. Smoking-related in- terstitial lung diseases: a concise review. Eur Respir J 2001;17: 122–32.

3. Hubbard R, Venn A, Smith C et al. Exposure to commonly pre- scribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case-control study. Am J Respir Crit Care Med 1998;157:743–7.

4. Bae W, Lee CH, Lee J et al. Impact of smoking on the development of idiopathic pulmonary fibrosis: results from a nationwide population-based cohort study. Thorax 2022;77:470–6.

5. Flaherty KR, Wells AU, Cottin V et al.; INBUILD Trial Investigators. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019;381:1718–27.

6. Distler O, Gahlemann M, Maher TM. Nintedanib for systemic sclerosis-associated interstitial lung disease. Reply. N Engl J Med 2019;381:1596–7.

7. Seibold MA, Wise AL, Speer MC et al. A common MUC5B pro- moter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364:1503–12.

8. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373:659–72.

9. Radner H, Smolen JS, Aletaha D. Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology (Oxford) 2011;50:381–8.

10. Smolen JS, Aletaha D, Barton A et al. Rheumatoid arthritis. Nat Rev Dis Primers 2018;4:18001.

11. Dudbridge F. Power and predictive accuracy of polygenic risk scores. PLoS Genet 2013;9:e1003348.

12. Suzuki A, Yamada R, Chang X et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003;34: 395–402.

13. Ozaki K, Ohnishi Y, Iida A et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002;32:650–4.

14. Juge PA, Lee JS, Ebstein E et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med 2018;379:2209–19.

15. Noth I, Zhang Y, Ma SF et al. Genetic variants associated with idi- opathic pulmonary fibrosis susceptibility and mortality: a genome- wide association study. Lancet Respir Med 2013;1:309–17.

16. Okada Y, Momozawa Y, Sakaue S et al. Deep whole-genome se- quencing reveals recent selection signatures linked to evolution and disease risk of Japanese. Nat Commun 2018;9:1631.

17. Shirai Y, Honda S, Ikari K et al. Association of the RPA3-UMAD1 locus with interstitial lung diseases complicated with rheumatoid arthritis in Japanese. Ann Rheum Dis 2020;79:1305–9.

18. Higuchi T, Oka S, Furukawa H, Shimada K, Tohma S. Lack of as- sociation of rs12702634 in RPA3-UMAD1 with interstitial lung diseases in Japanese rheumatoid arthritis patients. Biomark Insights 2022;17:11772719221091758.

19. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.

20. Raghu G, Remy-Jardin M, Myers JL et al.; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of idio- pathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018;198:e44–e68.

21. Atsumi T, Yamamoto K, Takeuchi T et al. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis 2016;75:75–83.

22. Tanaka Y, Kuwana M, Fujii T et al.; Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. 2019 Diagnostic criteria for mixed con- nective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoim- mune diseases. Mod Rheumatol 2021;31:29–33.

23. Bongartz T, Nannini C, Medina-Velasquez YF et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010;62:1583–91.

24. Gochuico BR, Avila NA, Chow CK et al. Progressive preclinical in- terstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008;168:159–66.

25. Kinoshita F, Hamano H, Harada H et al. Role of KL-6 in evaluat- ing the disease severity of rheumatoid lung disease: comparison with HRCT. Respir Med 2004;98:1131–7.

26. Stafford RL, Tang MY, Sawaya MR, Phillips ML, Bowie JU. Crystal structure of the central coiled-coil domain from human liprin-beta2. Biochemistry 2011;50:3807–15.

27. von Thun A, Birtwistle M, Kalna G et al. ERK2 drives tumour cell migration in three-dimensional microenvironments by suppressing expression of Rab17 and liprin-beta2. J Cell Sci 2012;125: 1465–77.

28. Wu Y, Yu H, Zheng SL et al. Germline mutations in PPFIBP2 are associated with lethal prostate cancer. Prostate 2018;78:1222–8.

29. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001;345:517–25.

30. Karch CM, Ezerskiy LA, Bertelsen S, Goate AM; Alzheimer’s Disease Genetics Consortium (ADGC). Alzheimer’s disease risk polymorphisms regulate gene expression in the ZCWPW1 and the CELF1 loci. PLoS One 2016;11:e0148717.

31. Roussos P, Mitchell AC, Voloudakis G et al. A role for non- coding variation in schizophrenia. Cell Rep 2014;9: 1417–29.

32. Son B, Kwon T, Lee S et al. CYP2E1 regulates the development of radiation-induced pulmonary fibrosis via ER stress- and ROS- dependent mechanisms. Am J Physiol Lung Cell Mol Physiol 2017; 313:L916–29.

33. Battelli LA, Ghanem MM, Kashon ML et al. Crystalline silica is a negative modifier of pulmonary cytochrome P-4501A1 induction. J Toxicol Environ Health A 2008;71:521–32.